Eva Gfrerer (AG Dötterl, 2022-10)
A chemical-ecological and evolutionary view on the deceptive pollination of Arum maculatum L. (Araceae)

Sabine Bernegger (AG Weßler, 2022-04)
The activity and role of HtrA in Helicobacter pylori pathogenesis

Jonathan Burghofer (AG Risch, 2022-04)
Highly Sensitive NGS Methods to Monitor Clonal Dynamics in Tumors Under Therapy

Arthur Hinterholzer (AG Cabrele, 2022-03)
Characterization of posttranslational modifications using NMR spectroscopy of denatured proteins

Martina Althammer (AG Tenhaken, 2022-02)
Molecular mechanisms of galactose toxicity in plants

Michael Stefan Kohlberger (AG Gadermaier, 2021-07)
Aptamers – optimized selection and use in biopharmaceutical characterisation

Muamera Sarajlic (AG Horejs-Höck, 2020-11)
H. pylori – a bacterial risk factor for gastric cancer

Luigi Grassi (AG Cabrele, 2019-09)
Synthesis and characterization of post-transnationally modified proteins of biological interest

Sara Huber (AG Gadermaier, 2019-04)
Mapping antibody profiles of Bet v 1 and associated food allergens during allergen-specific immunotherapy (AIT)

Eva König (AG Lackner, 2019-04)
Discovery and characterization of disease-related genetic variants

Eva Ivanov-Kavkova (AG Tenhaken, 2019-03)
Sugar kinases in plants

Maria Köhler (AG Tenhaken, 2019-03)
Analysis of the role of galactinol in nematode induced syncytia

Christof Regl (AG Huber, 2018-09)
Quantifizierung und aminosäurespezifische Zuweisung von posttranslationalen Modifikationen in monoklonalen Antikörpern

Sabrina Wildner (AG Gadermaier, 2018-06)
Structural features of biologics: characterization of allergen molecules and biopharmaceuticals

Lisa Strasser (AG Huber, 2018-04)
Investigation of phospho-signaling in cerebrolysin treated neuronal cells

Roman Gangl (AG Tenhaken, 2018-03)
Raffinose synthases and their contribution to the raffinose family oligosaccharide physiology in Arabidopsis

Robert Behmüller (AG Tenhaken, 2017-09)
The role of arabinokinase in the carbon supply for plant cells

Lorenz Aglas (AG Ferreira, 2017-08)
BM4SIT – An innovative causal therapy for allergy: safe and rapid induction of an antiinflammatory immune response using a mutant hypoallergen and vitamin D3

(Status as of 2022-10-28)